Immunovant, Inc. Annual Income Tax Expense (Benefit) in USD from 2018 to 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
Immunovant, Inc. quarterly/annual Income Tax Expense (Benefit) history and growth rate from 2018 to 2023.
  • Immunovant, Inc. Income Tax Expense (Benefit) for the quarter ending September 30, 2024 was $78K, a 82.8% decline year-over-year.
  • Immunovant, Inc. Income Tax Expense (Benefit) for the twelve months ending September 30, 2024 was $279K.
  • Immunovant, Inc. annual Income Tax Expense (Benefit) for 2023 was $567K, a 6200% increase from 2022.
  • Immunovant, Inc. annual Income Tax Expense (Benefit) for 2022 was $9K.
  • Immunovant, Inc. annual Income Tax Expense (Benefit) for 2021 was -$84K, a 76.5% increase from 2020.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Annual (USD)
Income Tax Expense (Benefit), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 $567K +$558K +6200% Apr 1, 2023 Mar 31, 2024 10-K 2024-05-29
2022 $9K +$93K Apr 1, 2022 Mar 31, 2023 10-K 2024-05-29
2021 -$84K +$274K +76.5% Apr 1, 2021 Mar 31, 2022 10-K 2023-05-22
2020 -$358K -$455K -469% Apr 1, 2020 Mar 31, 2021 10-K 2022-06-08
2019 $97K +$78K +411% Apr 1, 2019 Mar 31, 2020 10-K 2021-06-01
2018 $19K Apr 1, 2018 Mar 31, 2019 10-K 2020-06-29
* An asterisk sign (*) next to the value indicates that the value is likely invalid.